KA

KINETA INC
NASDAQ
4.100
+0.235
+6.08%
Closed 16:00 12/01 EST
OPEN
4.000
PREV CLOSE
3.865
HIGH
4.320
LOW
3.720
VOLUME
11.75K
TURNOVER
0
52 WEEK HIGH
9.00
52 WEEK LOW
1.780
MARKET CAP
42.61M
P/E (TTM)
-3.4422
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KA last week (1127-1201)?
Weekly Report · 31m ago
KINETA INC: Statement of changes in beneficial ownership of securities
Press release · 3d ago
Kineta To Host KOL Event To Review New Data From VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors On December 5, 2023
Kineta will host a virtual kol event to discuss new data from the vista-101 clinical trial of kva12123 in patients with advanced solid tumors. The event will feature presentations from two key opinion leaders in immuno-oncology. Michael a. Curran, ph.d. And evan y. Yu, m.d., will discuss the potential of vista blocking immunotherapy.
Benzinga · 5d ago
Weekly Report: what happened at KA last week (1120-1124)?
Weekly Report · 11/27 12:28
Weekly Report: what happened at KA last week (1113-1117)?
Weekly Report · 11/20 12:24
KINETA INC: Notice of Effectiveness
Press release · 11/15 14:46
KINETA INC: Prospectus [Rule 424(b)(3)]
Press release · 11/14 02:44
Weekly Report: what happened at KA last week (1106-1110)?
Weekly Report · 11/13 12:14
More
About KA
Kineta, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. Its innate immunity development platform aimed at developing human antibodies to address the mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets and research interests includes KVA12123, a monoclonal antibody (mAb), immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment. KVA12123 are primarily focused on solid tumors with high levels of VISTA expression.

Webull offers Kineta Inc stock information, including NASDAQ: KA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KA stock methods without spending real money on the virtual paper trading platform.